Prosensa Holding BV (RNA): Gr8 day and clean technical breakout ( f...

Gr8 day and clean technical breakout ( for

Whalatane · 2024-11-13T16:04:14.2330000Z

Gr8 day and clean technical breakout ( for those that follow such things ) Kiwi

Play Episode

6min

Proactive - Interviews for investors

Sprintex secures A$3.25m to expand global output; reduce debt

Sprintex Ltd (ASX:SIX) managing director and CEO Jay Upton talked with Proactive's Stephen Gunnion about the company’s successful A$3.25 million capital raise, drawing strong backing from both existing shareholders and new institutional investors. Upton said approximately A$1.5 million of the funds would go toward debt reduction, with the remaining A$1.75 million allocated to accelerating production and sales of Sprintex’s new range of high-speed electric compressors. These products aim to improve energy efficiency, offering “more than 50% energy savings versus the current benchmark products”. He discussed the company’s strategic manufacturing expansion, highlighting the transition of its Malaysian facility to support electric compressor production—mirroring current operations in Suzhou, China. This move is designed to double manufacturing capacity, navigate global trade sensitivities, and better serve regional preferences. Currently in the Netherlands, Upton also outlined a five-year partnership with Mest Water, a Dutch wastewater treatment firm focused on ammonia reduction in livestock manure—a project supported by the Dutch government. Sprintex will supply compressors for this initiative. Looking ahead, Sprintex is set to exhibit at the Hannover International Trade Fair in Germany, where the company expects to attract significant attention for its clean air and vacuum solutions across industries like aquaculture, semiconductors, textiles, and agriculture. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #Sprintex #CleanTech #IndustrialCompressors #EnergyEfficiency #GreenTechnology #CapitalRaise #Manufacturing #DutchTech #HannoverFair #VacuumTechnology #AsiaManufacturing #SustainableIndustry #AmmoniaReduction #ElectricCompressors

Proactive - Interviews for investors

BluGlass talks quantum sensing & commercial wins

BluGlass Head of Corporate and Investor Relations Stefanie Winwood talked with Proactive at the AIM's Small and Midcap Conference about the company’s work in gallium nitride (GaN) laser technology and its growing role in quantum sensing, computing, and defense applications. Winwood explained that gallium nitride is a compound semiconductor that can conduct electrons significantly faster than traditional silicon. BluGlass is one of a few companies globally producing visible lasers using GaN, a technology that is crucial in precision applications such as post-GPS navigation and quantum computing. “BluGlass is leading the market in the precision applications and these precision applications are the ones that are growing more rapidly,” Winwood said. The company works with large clients such as the US Department of Defense and major semiconductor players like General Electric and Coherent. BluGlass has recently secured contracts worth USD 6 million and aims to build long-term, revenue-generating relationships through projects that can lead to multi-decade manufacturing deals. In addition to commercial traction, BluGlass has strengthened its leadership with the appointment of industry veterans, including Nobel Laureate Shuji Nakamura. The company also recently demonstrated a world-record performance combining power and precision for quantum use cases. #BluGlass #QuantumComputing #GaNtechnology #GalliumNitride #Semiconductors #QuantumSensing #DefenseTech #LaserTechnology #InvestorUpdates #TechInnovation

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Proactive - Interviews for investors

Light Science Technologies CEO on Injecta Fire Barrier solution to UK's unsafe cladding dilemma

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the significant opportunity surrounding the company’s Injecta Fire Barrier solution, particularly in light of ongoing fire safety issues in the UK’s residential building sector. Deacon highlighted that the UK still has more than 33,000 buildings between 11m and 18m in height, and over 11,000 high-risk buildings above 18m, that require urgent fire protection measures. He referenced a government estimate suggesting a potential £22 billion cost to address the cladding crisis, which has persisted since the Grenfell tragedy. The Injecta Fire Barrier, acquired in late 2023, offers what Deacon described as a "unique solution"—one that avoids facade removal by injecting fire-resistant material directly into cavities, providing over two hours of fire resistance. He said, "We're three times less in cost and much quicker to install than traditional methods." He noted the division secured £2.7 million in orders during 2024, performing strongly and receiving positive feedback for its efficiency and clean delivery. With an average order value over £500,000 and significant market scope, Deacon framed the opportunity as a scalable revenue driver for the group. The company is targeting £50 million in revenue over the next five years, with Injecta Fire Barrier expected to be a key growth driver. 👉 For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #FireSafety #BuildingSafety #InjectaFireBarrier #LightScienceTechnologies #GrenfellLegacy #PropertyInvestment #ConstructionInnovation #FireProtection #CladdingCrisis #UKHousingSafety #ProactiveInvestors #SimonDeacon #BuildingRegulations #RealEstateSafety #PassiveFireProtection

Followers	131
Posts	21868
Boards Moderated	0
Alias Born	06/13/2011

Volume:	661
Day Range:
Bid:	25.02
Ask:	27.32
Last Trade Time:	6:03:09 AM EDT
Total Trades:	58

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

RNA Detailed Quote

Recent RNA News

More RNA News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent RNA News

Go Ad-Free